Serina Therapeutics, Inc. (SER) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
601 Genome Way
Huntsville, AL 35806
United States of America (the)
Phone
256 327 9630
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
January 21, 2000
| Name | Title | Pay | Year Born |
| Steven A. Ledger | Chief Executive Officer & Director | 637,500 | 1959 |
| J. Milton Harris | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board | 53,125 | 1941 |
| Gregory S. Curhan | Chief Financial Officer | 252,663 | 1962 |
| Balkrishan Gill | Executive Co-Chairman of the Board | 300,000 | 1965 |
| Srini Tenjarla | Chief Technical Operations Officer | 527,400 | 1962 |
| Randall W. Moreadith | Chief Development Officer | 563,200 | 1955 |
| Joshua Thomas | Head of Chemistry | 0 | N/A |
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.